http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005010025-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6240e178c9566d8d5578354139c8d386
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
filingDate 2004-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7d3792dda9865789e51bf68ba44dd72
publicationDate 2006-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005010025-A3
titleOfInvention Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
abstract The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g, alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one a2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate) and a suitable carrier.
priorityDate 2003-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004266776-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004156873-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11236066
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18350667
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917831
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227739292
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412955
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2435
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421079
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421078

Total number of triples: 29.